551 results on '"Barrett, P. Hugh R."'
Search Results
2. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)
3. Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a)
4. Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration
5. Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque
6. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin
7. Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults
8. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
9. A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production
10. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
11. Postprandial effects of a high salt meal on serum sodium, arterial stiffness, markers of nitric oxide production and markers of endothelial function
12. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
13. Acute Impact of Different Exercise Modalities on Arterial and Platelet Function
14. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies
15. Supplementation with n3 Fatty Acid Ethyl Esters Increases Large and Small Artery Elasticity in Obese Adults on a Weight Loss Diet
16. Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome
17. Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner
18. Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects
19. Personal model‐assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD
20. Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men
21. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease
22. Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism
23. Modeling the Male Reproductive Endocrine Axis: Potential Role for a Delay Mechanism in the Inhibitory Action of Gonadal Steroids on GnRH Pulse Frequency
24. Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men
25. Effects of atorvastatin and n−3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity
26. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia
27. Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment
28. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model
29. Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor
30. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism
31. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome
32. Influence of Simvastatin on apoB-100 Secretion in Non-Obese Subjects with Mild Hypercholesterolemia
33. Dose-Dependent Effects of Rosuvastatin on the Plasma Sphingolipidome and Phospholipidome in the Metabolic Syndrome
34. Effect of ω-3 Fatty Acid Ethyl Esters on Apolipoprotein B-48 Kinetics in Obese Subjects on a Weight-Loss Diet: A New Tracer Kinetic Study in the Postprandial State
35. Plasma Apolipoprotein B-48 Transport in Obese Men: A New Tracer Kinetic Study in the Postprandial State
36. Missense Mutations in APOB within the βα1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia
37. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism
38. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin
39. Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin
40. Dietary fatty acids and lipoprotein metabolism: new insights and updates
41. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model
42. Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies
43. Thematic review series: Patient-Oriented Research. Design and analysis of lipoprotein tracer kinetics studies in humans
44. Factorial study of the effect of n–3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity
45. Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma
46. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects
47. Apolipoprotein B-100 and ApoA-II Kinetics as Determinants of Cellular Cholesterol Efflux
48. Postprandial dyslipidaemia and diabetes: mechanistic and therapeutic aspects
49. Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-δ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity
50. Altered metabolism of apolipoprotein C-III: a contributor in chronic kidney disease?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.